SELLAS Life Sciences Group, Inc. (SLS) |
1.46 -0.06 (-3.95%) 04-26 16:00 |
Open: | 1.53 |
High: | 1.545 |
Low: | 1.4217 |
Volume: | 1,279,322 |
Market Cap: | 82(M) |
PE Ratio: | -1.09 |
Exchange: | NASDAQ Capital Market |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 2.01 |
Resistance 1: | 1.72 |
Pivot price: | 1.46 |
Support 1: | 1.25 |
Support 2: | 0.96 |
52w High: | 1.91 |
52w Low: | 0.5 |
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
EPS | -1.340 |
Book Value | -0.250 |
PEG Ratio | 0.00 |
Gross Profit | 0.000 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | 0.00 |
Return on Assets (ttm) | -174.3 |
Return on Equity (ttm) | 0.0 |
Fri, 19 Apr 2024
Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout (NASDAQ:SLS) - Seeking Alpha
Thu, 28 Mar 2024
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update - Yahoo Finance
Tue, 26 Mar 2024
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering ... - Yahoo Finance
Tue, 19 Mar 2024
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET - GlobeNewswire
Fri, 15 Mar 2024
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement ... - Yahoo Finance
Thu, 29 Feb 2024
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European ... - GlobeNewswire
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |